AI Article Synopsis
- A study involved 30 patients, primarily with peptic ulcers, treated with a new drug called lecedil, which blocks histamine H2-receptors.
- The drug's effectiveness was not dependent on the dosage, and there were no reported side effects, indicating good tolerance among patients.
- Results showed that 85% of duodenal ulcers healed within 4 weeks, while 95% healed by 5 weeks; 62.5% of gastric ulcers healed within 6 weeks, and 75% by 8 weeks.
Article Abstract
A total of 30 patients (29 with peptic ulcer and 2 with erosive gastroduodenitis) received lecedil, a new famotidine blocker of histamine H2-receptors. The effect of the drug was not related to the dose regimen (20 mg twice or 40 once a day). In good tolerance side effects were not reported. Healing of duodenal ulcer occurred within 4 and 5 treatment weeks in 17 (85.0%) and 19 (95.0%) out of 20 patients, respectively, within 6 and 8 treatment weeks ulcer healed in 5 and 6 out of 8 gastric ulcer patients, respectively.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
lecedil famotidine
8
patients peptic
8
treatment weeks
8
[effectiveness lecedil
4
famotidine therapy
4
patients
4
therapy patients
4
peptic ulcer]
4
ulcer] total
4
total patients
4
Similar Publications
Article Synopsis
- A study involved 30 patients, primarily with peptic ulcers, treated with a new drug called lecedil, which blocks histamine H2-receptors.
- The drug's effectiveness was not dependent on the dosage, and there were no reported side effects, indicating good tolerance among patients.
- Results showed that 85% of duodenal ulcers healed within 4 weeks, while 95% healed by 5 weeks; 62.5% of gastric ulcers healed within 6 weeks, and 75% by 8 weeks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!